JP2015533841A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015533841A5 JP2015533841A5 JP2015538330A JP2015538330A JP2015533841A5 JP 2015533841 A5 JP2015533841 A5 JP 2015533841A5 JP 2015538330 A JP2015538330 A JP 2015538330A JP 2015538330 A JP2015538330 A JP 2015538330A JP 2015533841 A5 JP2015533841 A5 JP 2015533841A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- mva
- identity
- promoter comprises
- copy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002773 nucleotide Substances 0.000 claims description 54
- 125000003729 nucleotide group Chemical group 0.000 claims description 54
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 14
- 150000007523 nucleic acids Chemical group 0.000 claims description 14
- 239000000427 antigen Substances 0.000 claims description 11
- 102000036639 antigens Human genes 0.000 claims description 11
- 108091007433 antigens Proteins 0.000 claims description 11
- 206010046865 Vaccinia virus infection Diseases 0.000 claims description 8
- 241000700605 Viruses Species 0.000 claims description 8
- 208000007089 vaccinia Diseases 0.000 claims description 8
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 4
- 241000282412 Homo Species 0.000 claims description 2
- 230000005867 T cell response Effects 0.000 claims description 2
- 230000006698 induction Effects 0.000 claims 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261719429P | 2012-10-28 | 2012-10-28 | |
| US61/719,429 | 2012-10-28 | ||
| PCT/EP2013/003239 WO2014063832A1 (en) | 2012-10-28 | 2013-10-28 | Pr13.5 promoter for robust t-cell and antibody responses |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019054129A Division JP6818797B2 (ja) | 2012-10-28 | 2019-03-22 | 強靭なｔ細胞用のｐｒ１３．５プロモータ及び抗体応答 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015533841A JP2015533841A (ja) | 2015-11-26 |
| JP2015533841A5 true JP2015533841A5 (enExample) | 2016-10-20 |
| JP6505016B2 JP6505016B2 (ja) | 2019-04-24 |
Family
ID=49513897
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015538330A Active JP6505016B2 (ja) | 2012-10-28 | 2013-10-28 | 強靭なｔ細胞用のｐｒ１３．５プロモータ及び抗体応答 |
| JP2019054129A Active JP6818797B2 (ja) | 2012-10-28 | 2019-03-22 | 強靭なｔ細胞用のｐｒ１３．５プロモータ及び抗体応答 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019054129A Active JP6818797B2 (ja) | 2012-10-28 | 2019-03-22 | 強靭なｔ細胞用のｐｒ１３．５プロモータ及び抗体応答 |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US9828414B2 (enExample) |
| EP (2) | EP2912183B1 (enExample) |
| JP (2) | JP6505016B2 (enExample) |
| KR (2) | KR102135818B1 (enExample) |
| CN (1) | CN104755622B (enExample) |
| AU (1) | AU2013337018B2 (enExample) |
| BR (1) | BR112015009320A2 (enExample) |
| CA (1) | CA2887623C (enExample) |
| CY (1) | CY1123181T1 (enExample) |
| DK (1) | DK2912183T3 (enExample) |
| EA (2) | EA032498B1 (enExample) |
| ES (1) | ES2800623T3 (enExample) |
| HK (1) | HK1212383A1 (enExample) |
| HU (1) | HUE049706T2 (enExample) |
| IL (1) | IL238130B (enExample) |
| IN (1) | IN2015DN03326A (enExample) |
| LT (1) | LT2912183T (enExample) |
| MX (2) | MX380483B (enExample) |
| MY (2) | MY194609A (enExample) |
| NZ (1) | NZ706637A (enExample) |
| PT (1) | PT2912183T (enExample) |
| SG (2) | SG10201704657WA (enExample) |
| SI (1) | SI2912183T1 (enExample) |
| UA (1) | UA118340C2 (enExample) |
| WO (1) | WO2014063832A1 (enExample) |
| ZA (1) | ZA201502892B (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA118340C2 (uk) * | 2012-10-28 | 2019-01-10 | Баваріан Нордік А/С | Промотор pr13.5 для стійких t-клітинних та гуморальних імунних реакцій |
| FR3042121A1 (fr) | 2015-10-08 | 2017-04-14 | Jean-Marc Limacher | Composition anti-tumorale |
| DK3407910T3 (da) | 2016-01-29 | 2022-07-18 | Bavarian Nordic As | Rekombinant modificeret vaccinia virus ankara (mva)-vaccine mod hesteencephalitisvirus |
| WO2017192418A1 (en) | 2016-05-02 | 2017-11-09 | Janssen Vaccine & Prevention B.V. | Therapeutic hpv vaccine combinations |
| CA3036799C (en) | 2016-09-28 | 2025-05-13 | Bavarian Nordic A/S | COMPOSITIONS AND METHODS FOR IMPROVING THE STABILITY OF TRANSGENES IN POXVIRUSES |
| WO2018091680A1 (en) | 2016-11-18 | 2018-05-24 | Transgene Sa | Cowpox-based oncolytic vectors |
| AU2017387549B2 (en) | 2016-12-28 | 2023-07-06 | Transgene Sa | Oncolytic viruses and therapeutic molecules |
| CA3066573A1 (en) * | 2017-06-15 | 2018-12-20 | Janssen Vaccines & Prevention B.V. | Poxvirus vectors encoding hiv antigens, and methods of use thereof |
| WO2019020543A1 (en) | 2017-07-28 | 2019-01-31 | Transgene Sa | ONCOLYTIC VIRUSES EXPRESSING AGENTS TARGETING METABOLIC IMMUNE MODULATORS |
| CA3073310A1 (en) | 2017-08-24 | 2019-02-28 | Bavarian Nordic A/S | Combination therapy for treating cancer with an intravenous administration of a recombinant mva and an antibody |
| AU2018389786A1 (en) | 2017-12-19 | 2020-06-18 | Bavarian Nordic A/S | Methods and compositions for inducing an immune response against hepatitis B virus (HBV) |
| GB201807932D0 (en) * | 2018-05-16 | 2018-06-27 | Redchenko Irina | Compositions and methods for inducing an immune response |
| WO2020011754A1 (en) | 2018-07-09 | 2020-01-16 | Transgene | Chimeric vaccinia viruses |
| CN110904127B (zh) | 2018-09-18 | 2024-09-20 | 瓦赫宁恩研究基金会 | 非洲猪瘟病毒疫苗 |
| IL281988B2 (en) | 2018-10-05 | 2025-03-01 | Bavarian Nordic As | Combination therapy for treating cancer with an intravenous administration of a recombinant mva and an immune checkpoint antagonist or agonist |
| CA3119503A1 (en) | 2018-11-20 | 2020-05-28 | Bavarian Nordic A/S | Therapy for treating cancer with an intratumoral and/or intravenous administration of a recombinant mva encoding 4-1bbl (cd137l) and/or cd40l |
| IL293009B1 (en) | 2019-11-20 | 2025-09-01 | Bavarian Nordic As | Recombinant mva viruses for intratumoral and/or intravenous administration for cancer treatment |
| IL298834A (en) | 2020-06-10 | 2023-02-01 | Bavarian Nordic As | A recombinant modified vaccinia virus ankara (mva) vaccine against coronavirus disease |
| US20220118081A1 (en) | 2020-10-20 | 2022-04-21 | Janssen Vaccines & Prevention B.V. | HIV vaccine regimens |
| KR20240051214A (ko) | 2021-09-03 | 2024-04-19 | 버베리안 노딕 에이/에스 | 변형 백시니아 바이러스 앙카라(mva)에 의한 세포독성 전이유전자 발현의 하향조절을 위한 마이크로rna의 활용 |
| WO2023118508A1 (en) | 2021-12-23 | 2023-06-29 | Bavarian Nordic A/S | Recombinant mva viruses for intraperitoneal administration for treating cancer |
| CA3240596A1 (en) | 2021-12-23 | 2023-06-29 | Cigdem ATAY LANGBEIN | Therapy for modulating immune response with recombinant mva encoding il-12 |
| KR20250029868A (ko) | 2022-06-29 | 2025-03-05 | 버베리안 노딕 에이/에스 | 재조합 변형 saRNA (VRP) 및 백시니아 바이러스 안카라 (MVA) 프라임-부스트 요법 |
| AU2023326730A1 (en) | 2022-08-18 | 2025-03-13 | Transgene | Chimeric poxviruses |
| IL321887A (en) | 2023-01-12 | 2025-09-01 | Bavarian Nordic As | Recombinantly modified Sarna (vrp) for cancer vaccine |
| FR3160186A1 (fr) | 2024-03-13 | 2025-09-19 | Odimma Therapeutics | Vecteur non-viral pour transcription augmentee |
| WO2025238218A1 (en) | 2024-05-17 | 2025-11-20 | Bavarian Nordic A/S | Viral vectors encoding antigen-displaying protein nanoparticles |
| WO2025238219A1 (en) | 2024-05-17 | 2025-11-20 | Bavarian Nordic A/S | Modified vaccinia virus ankara (mva) encoding antigen-displaying protein nanoparticles |
| WO2025238220A1 (en) | 2024-05-17 | 2025-11-20 | Bavarian Nordic A/S | Nucleic acids for vaccination encoding antigen-displaying protein nanoparticles |
| WO2025238221A1 (en) | 2024-05-17 | 2025-11-20 | Bavarian Nordic A/S | Viral vectors encoding multi-antigen-displaying protein nanoparticles |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9711957D0 (en) * | 1997-06-09 | 1997-08-06 | Isis Innovation | Methods and reagents for vaccination |
| GB9922361D0 (en) * | 1999-09-21 | 1999-11-24 | Isis Innovation | Generating an immune response to an antigen |
| UA76731C2 (uk) | 2000-11-23 | 2006-09-15 | Баваріан Нордік А/С | Штам mva-bn модифікованого вірусу коров'ячої віспи ankara, фармацевтична композиція, вакцина, застосування mva-bn для приготування лікарського препарату та для приготування вакцини, спосіб введення гомологічної і/або гетерологічної послідовності нуклеїнової кислоти в клітини-мішені in vitro, спосіб одержання пептиду або білка, спосіб одержання mva-bn, клітина, набір для основної/бустерної імунізації |
| ES2424847T3 (es) * | 2004-06-25 | 2013-10-09 | Merial Ltd. | Genes del virus de la fiebre aftosa que expresan avipox recombinantes |
| JP2008301792A (ja) * | 2007-06-11 | 2008-12-18 | National Univ Corp Shizuoka Univ | 改変ポリヘドリンプロモーター、バクミド変異体及び目的タンパク質の製造方法 |
| DK2367944T3 (en) | 2008-11-27 | 2019-04-15 | Bavarian Nordic As | PROMOTERS FOR RECOMBINANT VIRAL EXPRESSION |
| US8394385B2 (en) * | 2009-03-13 | 2013-03-12 | Bavarian Nordic A/S | Optimized early-late promoter combined with repeated vaccination favors cytotoxic T cell response against recombinant antigen in MVA vaccines |
| UA118340C2 (uk) * | 2012-10-28 | 2019-01-10 | Баваріан Нордік А/С | Промотор pr13.5 для стійких t-клітинних та гуморальних імунних реакцій |
-
2013
- 2013-10-28 UA UAA201505223A patent/UA118340C2/uk unknown
- 2013-10-28 CN CN201380054013.0A patent/CN104755622B/zh active Active
- 2013-10-28 HK HK16100267.8A patent/HK1212383A1/xx unknown
- 2013-10-28 KR KR1020157009206A patent/KR102135818B1/ko active Active
- 2013-10-28 US US14/437,939 patent/US9828414B2/en active Active
- 2013-10-28 HU HUE13783852A patent/HUE049706T2/hu unknown
- 2013-10-28 KR KR1020207020263A patent/KR20200087880A/ko not_active Ceased
- 2013-10-28 SG SG10201704657WA patent/SG10201704657WA/en unknown
- 2013-10-28 LT LTEP13783852.0T patent/LT2912183T/lt unknown
- 2013-10-28 CA CA2887623A patent/CA2887623C/en active Active
- 2013-10-28 AU AU2013337018A patent/AU2013337018B2/en active Active
- 2013-10-28 IN IN3326DEN2015 patent/IN2015DN03326A/en unknown
- 2013-10-28 NZ NZ706637A patent/NZ706637A/en unknown
- 2013-10-28 WO PCT/EP2013/003239 patent/WO2014063832A1/en not_active Ceased
- 2013-10-28 MY MYPI2018001787A patent/MY194609A/en unknown
- 2013-10-28 SG SG11201503200PA patent/SG11201503200PA/en unknown
- 2013-10-28 SI SI201331731T patent/SI2912183T1/sl unknown
- 2013-10-28 EP EP13783852.0A patent/EP2912183B1/en active Active
- 2013-10-28 MY MYPI2015701223A patent/MY171687A/en unknown
- 2013-10-28 BR BR112015009320A patent/BR112015009320A2/pt not_active Application Discontinuation
- 2013-10-28 MX MX2015005264A patent/MX380483B/es unknown
- 2013-10-28 ES ES13783852T patent/ES2800623T3/es active Active
- 2013-10-28 EA EA201590831A patent/EA032498B1/ru not_active IP Right Cessation
- 2013-10-28 EA EA201990114A patent/EA201990114A1/ru unknown
- 2013-10-28 DK DK13783852.0T patent/DK2912183T3/da active
- 2013-10-28 PT PT137838520T patent/PT2912183T/pt unknown
- 2013-10-28 EP EP20172647.8A patent/EP3778904A1/en active Pending
- 2013-10-28 JP JP2015538330A patent/JP6505016B2/ja active Active
-
2015
- 2015-04-02 IL IL238130A patent/IL238130B/en active IP Right Grant
- 2015-04-24 MX MX2021001638A patent/MX2021001638A/es unknown
- 2015-04-28 ZA ZA2015/02892A patent/ZA201502892B/en unknown
-
2017
- 2017-11-22 US US15/821,035 patent/US11028130B2/en active Active
-
2019
- 2019-03-22 JP JP2019054129A patent/JP6818797B2/ja active Active
-
2020
- 2020-07-08 CY CY20201100630T patent/CY1123181T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015533841A5 (enExample) | ||
| JP2018148890A5 (enExample) | ||
| JP2015524794A5 (enExample) | ||
| IN2015DN03326A (enExample) | ||
| JP2011155981A5 (enExample) | ||
| BR112016020688A2 (pt) | Composições úteis no tratamento da deficiência da ornitina transcarbamilase (otc) | |
| JP2016510989A5 (enExample) | ||
| JP2015524422A5 (enExample) | ||
| RU2019107976A (ru) | Композиция вакцины | |
| EA201590304A1 (ru) | Вакцина рекомбинантного модифицированного вируса осповакцины анкара респираторно-синцитиального вируса | |
| JP2014503206A5 (enExample) | ||
| FI3581650T3 (fi) | IX-tekijän polypeptidimutantti, sen käyttöjä ja menetelmä sen valmistamiseksi | |
| JP2018531624A5 (enExample) | ||
| JP2012515557A5 (enExample) | ||
| JP2017505605A5 (enExample) | ||
| EP2552490A4 (en) | INFLUENZA MATRIX 2 PROTEIN ECKTOMOMAS, EXPRESSION SYSTEM THEREFOR AND USES THEREOF | |
| WO2012106377A3 (en) | Nucleic acid molecules encoding novel herpes antigens, vaccine comprising the same, and methods of use thereof | |
| JP2016539946A5 (enExample) | ||
| MX2020000221A (es) | Secuencias de aminoacidos y de acidos nucleicos de adenovirus de grandes simios no humanos, vectores que contienen las mismas y usos de las mismas. | |
| WO2014018858A3 (en) | Multimeric fusion protein vaccine and immunotherapeutic | |
| JP2016529223A5 (enExample) | ||
| WO2012106231A3 (en) | Recombinant viral vectors and methods for inducing a heterosubtypic immune response to influenza a viruses | |
| WO2016073595A8 (en) | T cells and dendritic cells for polyomavirus therapy | |
| JP2014507146A5 (enExample) | ||
| JP2019508403A5 (enExample) |